ORAGENICS INC
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this amended report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: March 29, 2024
| ORAGENICS, INC. | |
|---|---|
| By: | /s/ J. Michael Redmond |
| J. Michael Redmond | |
| President and Interim Principal Executive Officer | |
POWER OF ATTORNEY
Each of the undersigned officers and directors of Oragenics, Inc., hereby constitutes and appoints J. Michael Redmond and Janet Huffman, their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for herself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| /s/ J. Michael Redmond | President, Interim Principal Executive Officer | March 29, 2024 |
|---|---|---|
| J. Michael Redmond | ||
| /s/ Janet Huffman | Chief Financial Officer, Secretary and Treasurer | March 29, 2024 |
| Janet Huffman | (Principal Accounting and Financial Officer) | |
| /s/ Robert. C. Koski | Director | March 29, 2024 |
| Robert C. Koski | ||
| /s/ Charles L. Pope | Chairman and Director | March 29, 2024 |
| Charles L. Pope | ||
| /s/ Frederick W. Telling | Director | March 29, 2024 |
| Frederick W. Telling | ||
| /s/ Alan W. Dunton | Director | March 29, 2024 |
| Alan W. Dunton | ||
| /s/ Bruce Cassidy | Director | March 29, 2024 |
| Bruce Cassidy | ||
| /s/ John Gandolfo | Director | March 29, 2024 |
| John Gandolfo | ||
| /s/ Kimberly Murphy | Director | March 29, 2024 |
| Kimberly Murphy | ||
Oragenics, Inc.
Years Ended December 31, 2023 and 2022
Index
| Index to Consolidated Financial Statements | |
|---|---|
| Report of Cherry Bekaert LLP, Independent Registered Public Accounting Firm (ID 00677) | F-2 |
| Report of Mayer Hoffman McCann P.C., Independent Registered Public Accounting Firm (PCAOB ID: 199) | F-3 |
| Audited Financial Statements | |
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Changes in Shareholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Consolidated Notes to Financial Statements | F-8 – F-19 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.